Tests wearable devices to estimate insulin-making cell function in type 1 diabetes
Tests wearables and glucose monitors in adults with type 1 diabetes.
Key facts
- Who runs it
- 4YouandMe
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- BETA - Pilot Study
- Status
- Enrolling by invitation
- People taking part
- 28 people, planned
- Started
- 1 Jul 2025
- Planned end
- 30 Nov 2025
- Type of study
- Observational
- Record updated
- 25 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Type 1 diabetes who live in the San Francisco Bay area, use a Dexcom CGM and a smartphone, and can travel to Novato, CA for in-person visits.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Established diagnosis of Type 1 diabetes. Self-reported HbA1c below 8% (64 mmol/mol). Body Mass Index 18-40 kg/m2.
- Earlier treatment
- If using long-acting insulin, it must be given only at bedtime and at no other time of day. People must not currently use certain medicines, including glucocorticoids, GLP-1 receptor agonists, SGLT inhibitors, DPP-4 inhibitors, sulfonylureas, meglitinides, metformin or thiazolidinediones. People must be willing to stop medicines containing acetaminophen during the study.
Main reasons for not taking part
- Pregnant or breastfeeding
- Current tobacco use
- Severe hypoglycemia or diabetes-related ketoacidosis in the past 6 months, or more than 2 episodes in the past 12 months
- Overnight hospitalization in the past 3 months
- Active cancer or chemotherapy within the past year
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- 18 years of age or older
- An established diagnosis of Type 1 diabetes
- Self-reported glycated hemoglobin (HbA1c) below 8% (64 mmol/mol)
- Body Mass Index 18-40 kg/m2
- Fluent in written and spoken English
- Own a personal iPhone 6s or later (iOS 15+ or newer) or Android smartphone (version 12 or newer) and willing to use this phone to download and use the app for the study
- Own a personal Dexcom CGM and willing to provide the study researchers access to it's data during the study
- Willing to use the study wearable devices (Oura ring, Empatica wristband)
- Resides in the San Francisco Bay area and willing to travel to Novato, CA on at least two occasions for the in person assessments at the Buck Institute
- If using long-acting insulin (e.g. Basaglar, Lantus, Levemir, Toujeo, Tresiba), must be on a dosing schedule that involves administration of insulin only at bedtime and no other times of day
- Willing to stop use of prescription or over-the-counter medications containing acetaminophen (e.g. Tylenol, Percocet, Nyquil and other common medications for cold and flu, etc.) due to potential interference with the study-provided continuous glucose monitor
Who cannot take part
- History of severe hypoglycemia or diabetes-related ketoacidosis in the prior 6 months or >2 episodes in the past 12 months
- Allergy to dairy or soy
- History of pancreatic disease (other than diabetes) or pancreatic transplantation
- Active malignancy or chemotherapy for malignancy within the past year
- History of bariatric surgery or other gastrointestinal surgery anticipated to affect glucose metabolism, or any cause of gastroparesis
- Renal, hepatic, cardiovascular, or other systemic disease likely to interfere with glucose metabolism or study participation
- Current use of the following medications: Calcium channel blockers (e.g., verapamil), glucocorticoids, non-selective beta blockers (e.g., propranolol), GLP-1 receptor agonists, SGLT inhibitors, DPP-4 inhibitors, sulfonylureas, meglitinides, metformin, or thiazolidinediones
- Pregnant or breastfeeding
- Current tobacco use
- Overnight hospitalization for any reason in the past 3 months
Where in United States
- Buck Institute for Research on AgingSan Francisco, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This study is testing the feasibility of using non-invasive, remote digital tools including continuous glucose monitors (CGMs) and Oura ring and the Empatica EmbracePlus smart wristband to predict the function of beta-cells, the cells in the pancreas that secrete insulin. This study is being initially done with individuals with Type 1 diabetes, so that in the future these methods can be tested in a larger study of individuals with Type 2 diabetes or prediabetics. The eventual aim of this work is to develop remote digital tools that can predict the health and functioning of the pancreas in people with prediabetes and Type 2 diabetes, allowing personalized treatment approaches to preserve insulin secretion.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Beta-cell Evaluation Through Data-driven Assessments (BETA): Pilot Study in Type 1 Diabetes
- Plain-language title
- Tests wearable devices to estimate insulin-making cell function in type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 September 2025